Skip to content

Pfizer

NYSE: PFE · USD

Pfizer cash flow and EPS78

Operating cash flow, capital investment, free cash flow and earnings per share.

Capital allocation

% of tracked cash uses

$533M
Pfizer capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q230.78% · $269MUnavailableUnavailableUnavailable69.22% · $605M100% · $874M
FY 2009 Q399.24% · $261M0% · $0M0% · $0MUnavailable0.76% · $2M100% · $263M
FY 2009 Q40.97% · $422M98.9% · $43,123M0% · $0MUnavailable0.13% · $57M100% · $43,602M
FY 2010 Q197.13% · $305MUnavailableUnavailableUnavailable2.87% · $9M100% · $314M
FY 2010 Q2100% · $373MUnavailableUnavailableUnavailableUnavailable100% · $373M
FY 2010 Q336.46% · $288MUnavailable63.29% · $500MUnavailable0.25% · $2M100% · $790M
FY 2010 Q499.64% · $547MUnavailable0% · $0MUnavailable0.36% · $2M100% · $549M
FY 2011 Q12.86% · $250M36.31% · $3,169M16.39% · $1,430MUnavailable44.44% · $3,878M100% · $8,727M
FY 2011 Q213.73% · $358M0% · $0M86.27% · $2,249MUnavailableUnavailable100% · $2,607M
FY 2011 Q317.54% · $454M0.73% · $19M81.53% · $2,110MUnavailable0.19% · $5M100% · $2,588M
FY 2011 Q48.08% · $598M1.27% · $94M43.37% · $3,211MUnavailable47.28% · $3,500M100% · $7,403M
FY 2012 Q19.41% · $254M28.98% · $782M61.49% · $1,659MUnavailable0.11% · $3M100% · $2,698M
FY 2012 Q217.95% · $294M0% · $0M81.81% · $1,340MUnavailable0.24% · $4M100% · $1,638M
FY 2012 Q313.4% · $285M0% · $0M86.27% · $1,835MUnavailable0.33% · $7M100% · $2,127M
FY 2012 Q48.74% · $494M4.74% · $268M60.02% · $3,394MUnavailable26.51% · $1,499M100% · $5,655M
FY 2013 Q14.18% · $202M0% · $0M95.78% · $4,626MUnavailable0.04% · $2M100% · $4,830M
FY 2013 Q25.17% · $309M0.25% · $15M54.57% · $3,263MUnavailable40.01% · $2,392M100% · $5,979M
FY 2013 Q36.89% · $278M0% · $0M93.06% · $3,754MUnavailable0.05% · $2M100% · $4,034M
FY 2013 Q46.12% · $417M0% · $0M68.2% · $4,647MUnavailable25.68% · $1,750M100% · $6,814M
FY 2014 Q113.03% · $292M0% · $0M53.41% · $1,197MUnavailable33.56% · $752M100% · $2,241M
FY 2014 Q217.36% · $278M0% · $0M82.64% · $1,323MUnavailable0% · $0M100% · $1,601M
FY 2018 Q213.36% · $424M0% · $0M0% · $0MUnavailable86.64% · $2,749M100% · $3,173M
FY 2018 Q333.11% · $547M0% · $0M66.89% · $1,105MUnavailable0% · $0M100% · $1,652M
FY 2018 Q411.09% · $685M0% · $0M81.43% · $5,030MUnavailable7.48% · $462M100% · $6,177M
FY 2019 Q13.73% · $460MUnavailable71.9% · $8,865MUnavailable24.37% · $3,004M100% · $12,329M
FY 2019 Q216.93% · $479MUnavailable0% · $0MUnavailable83.07% · $2,351M100% · $2,830M
FY 2019 Q355.61% · $565MUnavailable0% · $0MUnavailable44.39% · $451M100% · $1,016M
FY 2019 Q440.19% · $672M0% · $0M0% · $0MUnavailable59.81% · $1,000M100% · $1,672M
FY 2020 Q117.51% · $463MUnavailable0% · $0MUnavailable82.49% · $2,181M100% · $2,644M
FY 2020 Q2100% · $479MUnavailable0% · $0MUnavailable0% · $0M100% · $479M
FY 2020 Q361.4% · $525MUnavailable0% · $0MUnavailable38.6% · $330M100% · $855M
FY 2020 Q434.48% · $785M0% · $0M0% · $0MUnavailable65.52% · $1,492M100% · $2,277M
FY 2021 Q1100% · $554M0% · $0M0% · $0MUnavailable0% · $0M100% · $554M
FY 2021 Q2100% · $540M0% · $0M0% · $0MUnavailable0% · $0M100% · $540M
FY 2021 Q338.4% · $624M0% · $0M0% · $0MUnavailable61.6% · $1,001M100% · $1,625M
FY 2021 Q449.75% · $993M0% · $0M0% · $0MUnavailable50.25% · $1,003M100% · $1,996M
FY 2022 Q16.14% · $643M59.42% · $6,225M19.09% · $2,000MUnavailable15.36% · $1,609M100% · $10,477M
FY 2022 Q2100% · $751M0% · $0M0% · $0MUnavailable0% · $0M100% · $751M
FY 2022 Q3100% · $841M0% · $0M0% · $0MUnavailable0% · $0M100% · $841M
FY 2022 Q45.14% · $1,001M86.18% · $16,772M0% · $0MUnavailable8.68% · $1,689M100% · $19,462M
FY 2023 Q180.89% · $1,139M0% · $0M0% · $0MUnavailable19.11% · $269M100% · $1,408M
FY 2023 Q247.14% · $914M1.29% · $25M0% · $0MUnavailable51.57% · $1,000M100% · $1,939M
FY 2023 Q338.39% · $810M0% · $0M0% · $0MUnavailable61.61% · $1,300M100% · $2,110M
FY 2023 Q42.35% · $1,044M97.65% · $43,405M0% · $0MUnavailable0% · $0M100% · $44,449M
FY 2024 Q136.03% · $704MUnavailableUnavailableUnavailable63.97% · $1,250M100% · $1,954M
FY 2024 Q238.91% · $637MUnavailableUnavailableUnavailable61.09% · $1,000M100% · $1,637M
FY 2024 Q3100% · $651M0% · $0MUnavailableUnavailable0% · $0M100% · $651M
FY 2024 Q4100% · $917M0% · $0MUnavailableUnavailable0% · $0M100% · $917M
FY 2025 Q1100% · $564MUnavailableUnavailableUnavailable0% · $0M100% · $564M
FY 2025 Q214.15% · $618MUnavailableUnavailableUnavailable85.85% · $3,750M100% · $4,368M
FY 2025 Q3100% · $602MUnavailableUnavailableUnavailable0% · $0M100% · $602M
FY 2025 Q421.94% · $845MUnavailableUnavailableUnavailable78.06% · $3,007M100% · $3,852M
FY 2026 Q1100% · $436MUnavailableUnavailableUnavailableUnavailable100% · $436M
FY 2026 Q2100% · $533MUnavailableUnavailableUnavailableUnavailable100% · $533M
Jun 28, 2009 through Jun 28, 2026

Latest period omits acquisitions, buybacks, dividends, debt repayments. Percentages cover tracked uses. SBC is noncash and excluded.

Operating cash flow

USD millions

$835M

Capital expenditures

USD millions

$533M

Free cash flow

USD millions

$302M

Stock-based compensation

USD millions

$249M

SBC / free cash flow

% · FCF before SBC deduction

82.45%

SBC / operating cash flow

%

29.82%

Software & intangible investment

USD millions

—

Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.

Diluted EPS

USD per share

$-0.04

Quarterly data

Pfizer cash-flow history. Each metric has its own unit. A dash means inputs are missing or the calculation is undefined.
Fiscal periodEndedOperating cash flowUSD millionsCapital expendituresUSD millionsFree cash flowUSD millionsStock-based compensationUSD millionsSBC / free cash flow%SBC / operating cash flow%Software & intangible investmentUSD millionsDiluted EPSUSD per share
FY 2026 Q2Jun 28, 202683553330224982.45%29.82%—$-0.04
FY 2026 Q1Mar 29, 20262,6154362,17927212.48%10.4%—$0.47
FY 2025 Q4Dec 31, 20255,3488454,5032255%4.21%——
FY 2025 Q3Sep 28, 20254,6036024,0012015.02%4.37%—$0.62
FY 2025 Q2Jun 29, 2025-582618-1,200203———$0.51
FY 2025 Q1Mar 30, 20252,3355641,7711709.6%7.28%—$0.52
FY 2024 Q4Dec 31, 20246,7219175,8041773.05%2.63%——
FY 2024 Q3Sep 29, 20246,7146516,0632744.52%4.08%—$0.78
FY 2024 Q2Jun 30, 2024-1,781637-2,418206———$0.01
FY 2024 Q1Mar 31, 20241,09070438622056.99%20.18%—$0.55
FY 2023 Q4Dec 31, 20235,2401,0444,1961212.88%2.31%——
FY 2023 Q3Oct 1, 20233,4568102,6461515.71%4.37%—$-0.42
FY 2023 Q2Jul 2, 2023-1,208914-2,122148———$0.41
FY 2023 Q1Apr 2, 20231,2121,13973105143.84%8.66%—$0.97
FY 2022 Q4Dec 31, 20228,5821,0017,5813644.8%4.24%——
FY 2022 Q3Oct 2, 20225,9748415,1331352.63%2.26%—$1.51
FY 2022 Q2Jul 3, 20228,1707517,4192873.87%3.51%—$1.73
FY 2022 Q1Apr 3, 20226,5416435,898861.46%1.31%—$1.37
FY 2021 Q4Dec 31, 20215,9149934,92149510.06%8.37%——
FY 2021 Q3Oct 3, 202110,82962410,2052932.87%2.71%—$1.42
FY 2021 Q2Jul 4, 202111,29954010,7592222.06%1.96%—$0.98
FY 2021 Q1Apr 4, 20214,5385543,9841724.32%3.79%—$0.86
FY 2020 Q4Dec 31, 20205,6257854,8402645.45%4.69%——
FY 2020 Q3Sep 27, 20202,0905251,56523414.95%11.2%—$0.37
FY 2020 Q2Jun 28, 20203,5554793,0761946.31%5.46%—$0.58
FY 2020 Q1Mar 29, 20203,1334632,670642.4%2.04%—$0.58
FY 2019 Q4Dec 31, 20193,7696723,0972708.72%7.16%——
FY 2019 Q3Sep 29, 20194,5105653,945641.62%1.42%—$1.29
FY 2019 Q2Jun 30, 20192,6114792,1321999.33%7.62%—$0.84
FY 2019 Q1Mar 31, 20191,6984601,23818514.94%10.9%—$0.65
FY 2018 Q4Dec 31, 20184,7386854,0532676.59%5.64%——
FY 2018 Q3Sep 30, 20185,2595474,7123036.43%5.76%—$0.65
FY 2018 Q2Jul 1, 20183,8474243,4231975.76%5.12%—$0.62
FY 2014 Q2Jun 29, 20144,0872783,8091383.62%3.38%—$0.43
FY 2014 Q1Mar 30, 20142,9352922,6431435.41%4.87%—$0.34
FY 2013 Q4Dec 31, 20135,7864175,3691051.96%1.81%——
FY 2013 Q3Sep 29, 20135,9082785,6301262.24%2.13%—$0.37
FY 2013 Q2Jun 30, 20133,8303093,5211032.93%2.69%—$1.88
FY 2013 Q1Mar 31, 20132,2412022,0391899.27%8.43%—$0.36
FY 2012 Q4Dec 31, 20125,2564944,7621192.5%2.26%——
FY 2012 Q3Sep 30, 20125,0032854,7181152.44%2.3%—$0.41
FY 2012 Q2Jul 1, 20124,0212943,7271173.14%2.91%—$0.41
FY 2012 Q1Apr 1, 20122,7742542,5201305.16%4.69%—$0.23
FY 2011 Q4Dec 31, 20115,2615984,663721.54%1.37%——
FY 2011 Q3Oct 2, 20114,4394543,9851032.58%2.32%—$0.46
FY 2011 Q2Jul 3, 20115,8983585,5401222.2%2.07%—$0.31
FY 2011 Q1Apr 3, 20114,6422504,3921222.78%2.63%—$0.27
FY 2010 Q4Dec 31, 20106,2585475,711540.95%0.86%——
FY 2010 Q3Oct 3, 20106,6832886,3951081.69%1.62%—$0.1
FY 2010 Q2Jul 4, 20104,8733734,5001052.33%2.15%—$0.29
FY 2010 Q1Apr 4, 2010-6,360305-6,665138———$0.24
FY 2009 Q4Dec 31, 20094,8254224,403912.07%1.89%——
FY 2009 Q3Sep 27, 20094,1012613,840892.32%2.17%—$0.41
FY 2009 Q2Jun 28, 20094,5142694,245982.31%2.17%—$0.32
Sources and calculations

Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.

Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.

FCF subtracts reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Acquisitions and noncash lease additions are excluded. EPS and weighted shares are not summed across quarters. Annual figures use annual reports.

SBC / FCF always uses FCF before SBC deduction; both SBC ratios compare amounts from the same period. A zero or negative cash-flow denominator is undefined, and values above 100% are retained.

Each reported nonnegative cash use / sum of available tracked nonnegative cash uses × 100. Missing categories are omitted, never set to zero. This is the composition of tracked uses, not a complete cash-flow reconciliation or a percentage of OCF. SBC is noncash and excluded. Negative amounts are excluded as reversals or net receipts; they are not converted to spending. Annual bars use reported annual amounts. Turning off a category hides its share without changing the denominator. Debt repayments prefer a reported aggregate, with long-term or convertible-only scope identified in the tooltip. Acquisitions are net of cash acquired. Dividend payments use the aggregate where reported, including dividend equivalents when part of that concept.

The SBC option subtracts reported share-based compensation from FCF as an economic-cost scenario. Missing SBC never becomes zero.

Market prices: Yahoo Finance · PFE, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.

Operating cash flow
Reported net cash provided by or used in operating activities.
Capital expenditures
Reported cash capital investment. Uses purchases of property, plant and equipment where disclosed; otherwise purchases of productive assets, which can also include software and intangibles. Excludes acquisitions and noncash lease additions.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Stock-based compensation
Reported share-based compensation addback in the cash-flow statement. Missing disclosure is not treated as zero.
SBC / free cash flow
Reported share-based compensation / (operating cash flow − cash capital investment) × 100, for the same fiscal period. Always uses FCF before SBC deduction. Zero or negative FCF is undefined; values above 100% are retained.
SBC / operating cash flow
Reported share-based compensation / reported operating cash flow × 100, for the same fiscal period. Zero or negative operating cash flow is undefined. Unaffected by the SBC deduction scenario.
Software & intangible investment
Separately tagged payments for capitalized software under US GAAP, or purchases of intangible assets under IFRS. This optional disclosure is not inferred from total capex or deducted a second time from FCF.
Diluted EPS
Reported diluted earnings per share, normalized for recorded subsequent stock splits. Quarterly EPS is never subtracted from annual or YTD EPS.